Skip to main content

Pharma E-Detailer Localization Automation: The Figma Plugin Fix

Digital Transformation·7 min read

The three-day problem nobody talks about

A 40-slide e-detailer going into five markets used to burn roughly three designer-days per language on a single task: moving text in and out of Figma. Export the copy block by block. Paste it into Excel. Send the sheet to the local affiliate. Wait. Receive it back. Re-import by hand. Re-align every text box because the French ran 30% longer than the English and the German pushed a CTA off the safe zone.

That is not design work. That is copy-paste work wearing a designer's job title.

When Promedia mapped where AI could actually earn its keep in pharma design, this was the first candidate. Not writing the detail aid. Not making medical claims. Not deciding brand treatment. Just moving the content through the pipeline without a human babysitting it. Research from Smartcat on pharma translation trends found that high-ROI teams are 6.5 times more likely to report 50%+ faster localization workflows when AI is applied at the process level rather than one-off tasks, with process automation delivering 60% ROI compared to 15% for fully human-driven workflows. The math backs up what designers already feel.

How to automate e-detailer localization in Figma

The pattern is straightforward once you stop trying to make AI write the content. A Figma plugin reads the file structure, identifies every copy block across every slide, and extracts it into a structured file that preserves the link between each string and its exact location: slide number, layer name, component ID, style token.

The local market team never touches Figma. They work in their own language, in their own translation or review tool, with their own medical and regulatory sign-off process. When the approved copy comes back, one click re-imports it. Text boxes resize to fit the new string length. Styles hold. Auto-layout handles the ripple. Component overrides stay intact.

What changes for the designer:

  • No more manual export of 40 slides into a spreadsheet
  • No more re-pasting 200 strings into the right text boxes
  • No more re-aligning layouts because German expanded by 35%
  • No more version drift between the master file and five market variants
  • Time back for the creative and brand work that actually needs a human

This sits inside Promedia's broader AI Design System offer, which builds Figma plugins and AI agents around a client's actual design system rather than a generic template. The plugin knows your components, your tokens, and your brand rules because it was built against them.

How can AI reduce manual work in pharma detail aid production

The honest answer: AI should take the repetitive, low-value work off the plate and leave the judgement calls alone. Viseven's work on content localization best practices lands in the same place, noting that AI supports pharma localization through machine translation, terminology extraction, source optimization, and QA checks at scale, while human expertise and regulatory oversight stay essential at every stage.

Inside a detail aid production workflow, that means AI is a strong fit for:

  • Extracting and re-importing copy across Figma files
  • Running WCAG 2.2 accessibility checks against every component
  • Maintaining design tokens when brand guidelines update
  • Parsing brand PDFs into a usable design system
  • Generating documentation that nobody wants to write but everyone needs to read

AI is a bad fit for medical claims, brand tone decisions, regulatory interpretation, and final creative sign-off. The test Promedia applies to any new AI use case is simple: does it protect brand consistency and free up human time for decisions that actually matter? If yes, build it. If not, skip it.

How do you maintain brand consistency across multi-market e-detailers

Consistency breaks in the handoffs. Every time copy leaves the design file and comes back, something drifts: a font override, a colour token, a spacing value that got nudged by a well-meaning reviewer. Across five markets and three revision rounds, the drift compounds.

Automating the extraction and re-import step closes most of these gaps because the copy never leaves its structural anchor. The plugin writes the translated string back into the exact layer it came from, applying the exact style token that was already there. Local markets cannot accidentally break the brand because they never touch the design file.

The second layer is automated compliance checking. Promedia's WCAG 2.2 plugin scans a design system library in minutes rather than the weeks a manual audit takes, flagging contrast failures, touch target issues, and heading hierarchy problems with prioritized fixes. For teams with European Accessibility Act obligations, this turns a quarterly scramble into a continuous check that runs every time the library updates.

Brand consistency, in other words, stops being a review-stage catch and becomes a build-stage guarantee.

What is the fastest way to localize a pharma e-detailer

The fastest route is the one that removes the most handoffs. In practice that means:

  1. Build the master e-detailer in Figma with a locked component library and proper auto-layout so text expansion does not break slides
  2. Extract all copy in one click into a structured file that preserves slide, layer, and component references
  3. Route the file to local markets for translation, medical review, and regulatory sign-off in their preferred tools
  4. Re-import the approved copy in one click, letting the plugin handle layout adjustments automatically
  5. Run an automated WCAG and brand compliance scan before final export

PwC's work on AI-powered personalization describes this as 'glocalization', where local teams adapt global strategy to market-specific needs while central brand and regulatory control holds. Smartcat's pharma analysis makes the same point from the operations side: structured AI workflows let teams update compliance content across multiple markets in shorter timeframes without expanding headcount.

The measurable outcome is what matters. A localization pass that used to take three designer-days per language runs in a morning. The designer goes back to designing. The affiliate gets their market version faster. The brand team stops fielding frantic Slack messages about misaligned text boxes.

Frequently asked questions

What does an e-detailer localization workflow look like in pharma?

A typical workflow has four stages: the designer builds a master file in Figma, copy is exported to local markets for translation and medical-regulatory review, the approved copy is re-imported into the design file, and the localized version goes through final QA before export to the e-detailing platform. Historically stages two and three are manual and slow. Automation collapses them into a round trip that preserves layout and brand integrity.

Can AI automate copy extraction from Figma for pharma teams?

Yes, through a custom Figma plugin that reads the file structure and exports copy into a structured file linked to each string's slide, layer, and component. Promedia builds these plugins against the client's actual design system so the extraction and re-import respect existing components and tokens. The AI is doing mechanical routing, not writing or editing content, which keeps the workflow compliant with medical and regulatory review.

How do you scale e-detailer production across multiple markets without increasing headcount?

By automating the process-level work: extraction, re-import, accessibility checks, token maintenance, and brand integration. Smartcat's pharma research found that process-level automation delivers around 60% ROI compared to 15% for human-only workflows, largely because it removes the bottlenecks that force teams to hire more designers just to keep pace with market demand.

What tasks should AI handle in pharma design, and what should stay human?

AI should handle repetitive, low-value, rule-based work: extraction, re-import, WCAG scans, documentation, token updates, brand PDF parsing. Humans should own creative decisions, medical judgement, regulatory interpretation, and final brand sign-off. Promedia's internal test is whether a use case protects brand consistency and frees human time for decisions that matter. Anything else is automation for its own sake.

Where to start

If multi-market e-detailer rollouts are eating your timeline, the leverage point is almost never the translation itself. It is the handoff between Figma and the market. Fix that, and the rest of the production schedule relaxes.

Promedia builds Figma plugins and AI agents against the client's own design system, so the automation respects the components, tokens, and brand rules already in place. If you want to see how the e-detailer localization plugin works on a real file, a short working session is usually enough to show whether it fits your workflow.

Get pharma comms insights.

One short email when we publish. No spam, no sales pitch. Unsubscribe whenever.